Aishaini Puvanendran
About Aishaini Puvanendran
Aishaini Puvanendran is a Senior Project Manager at BenevolentAI in London, focusing on AI safety and ethics in drug discovery.
Current Position at BenevolentAI
Aishaini Puvanendran is currently a Senior Project Manager at BenevolentAI, based in London, United Kingdom. In this role, she manages complex projects focused on transforming the drug discovery process through AI. Her work involves overseeing collaborations that aim to integrate various aspects of artificial intelligence to expedite and enhance research outcomes in the pharmaceutical industry.
Previous Experience at PwC
Before her current role, Aishaini Puvanendran worked at PricewaterhouseCoopers Limited as an Actuarial Consultant from 2013 to 2019 in London, United Kingdom. Her work at PwC involved actuarial consulting, where she specialized in risk modelling, focusing on natural catastrophe modelling and latent health hazards. This experience honed her skills in risk assessment and provided a solid foundation in quantitative analysis.
Education Background at UCL
Aishaini Puvanendran completed her Bachelor's degree in Natural Sciences from University College London (UCL). She studied at UCL from 2008 to 2011, earning a BSc degree. Her academic background in Natural Sciences provided a broad understanding of scientific principles, which she has applied in various professional contexts throughout her career.
Focus on AI Safety and Ethics
Aishaini Puvanendran has a strong interest in AI safety and ethics, which motivated her transition to BenevolentAI. She aims to contribute to the ethical deployment of artificial intelligence technologies, ensuring that these technologies are used to create equal treatment opportunities for everyone. This includes addressing issues of underrepresentation and exclusion of certain groups from research data to foster more inclusive and equitable AI applications.
Commitment to Ethical AI and Inclusion in Research
At BenevolentAI, Aishaini Puvanendran's work involves actively addressing the underrepresentation and exclusion of certain groups from research data. She is dedicated to promoting ethical AI practices that ensure fair treatment and inclusivity in AI-powered drug discovery processes. Her efforts contribute to setting higher standards for ethical considerations in AI, aiming for the responsible development and deployment of advanced technologies in the field.